In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
The efficacy of dipyrone to modulate antitumor activity of mitoxantrone (MTN) and doxorubicin (DOX) was studied in vivo in mice bearing P388 murine lymphocytic leukemia sensitive (P388/S) and resistant P388/DOX) to DOX. P388/DOX-bearing mice demonstrated marginally higher sensitivity to dipyrone at 200 mg/kg when compared to P388/S-bearing mice. However, dipyrone could significantly enhance the antitumor activity of MTN and DOX in both P388/S and P388/DOX-tumor-bearing mice. MTN was cross-resistant to P388/DOX.
Kamath
N S
NS
Cellular Chemotherapy Unit, Tata Memorial Center, Parel, Bombay, India.
Chitnis
M P
MP
D000632:Aminopyrine / Q000031:analogs & derivatives*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002463:Cell Membrane Permeability / Q000187:drug effects; D004177:Dipyrone / Q000008:administration & dosage* / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000627:therapeutic use
D000632:Aminopyrine; D004177:Dipyrone; D004317:Doxorubicin; D008942:Mitoxantrone